Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Mirtazapine attenuates cocaine seeking in rats.

Barbosa-Méndez S, Leff P, Arías-Caballero A, Hernández-Miramontes R, Heinze G, Salazar-Juárez A.

J Psychiatr Res. 2017 Sep;92:38-46. doi: 10.1016/j.jpsychires.2017.03.021. Epub 2017 Apr 4.

PMID:
28391178
2.

Mirtazapine prevents induction and expression of cocaine-induced behavioral sensitization in rats.

Salazar-Juárez A, Barbosa-Méndez S, Jurado N, Hernández-Miramontes R, Leff P, Antón B.

Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jul 4;68:15-24. doi: 10.1016/j.pnpbp.2016.02.010. Epub 2016 Feb 26.

PMID:
26922897
3.

Is it important to consider the sex of the patient when using lithium or valproate to treat the bipolar disorder?

Flores-Ramos M, Leff P, Fernández-Guasti A, Becerra Palars C.

Pharmacol Biochem Behav. 2017 Jan;152:105-111. doi: 10.1016/j.pbb.2016.02.003. Epub 2016 Feb 14. Review. No abstract available.

PMID:
26883244
4.

Differences in asthma study models and the effectiveness of β2 -adrenoceptor ligands: response to Lipworth et al.

Bond RA, Thanawala VJ, Parra S, Leff P.

Br J Pharmacol. 2016 Jan;173(1):250-1. doi: 10.1111/bph.13334. No abstract available.

5.

β-Blockers have differential effects on the murine asthma phenotype.

Thanawala VJ, Valdez DJ, Joshi R, Forkuo GS, Parra S, Knoll BJ, Bouvier M, Leff P, Bond RA.

Br J Pharmacol. 2015 Oct;172(20):4833-46. doi: 10.1111/bph.13253. Epub 2015 Oct 13.

6.

Ligand bias prevents class equality among beta-blockers.

Thanawala VJ, Forkuo GS, Stallaert W, Leff P, Bouvier M, Bond R.

Curr Opin Pharmacol. 2014 Jun;16:50-7. doi: 10.1016/j.coph.2014.03.002. Epub 2014 Mar 27. Review.

7.

An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation. 1985.

Black JW, Leff P, Shankley NP, Wood J.

Br J Pharmacol. 2010 Jul;160 Suppl 1:S54-64. doi: 10.1111/j.1476-5381.2010.00855.x. No abstract available.

8.

Proinflammatory cytokine levels in fibromyalgia patients are independent of body mass index.

Hernandez ME, Becerril E, Perez M, Leff P, Anton B, Estrada S, Estrada I, Sarasa M, Serrano E, Pavon L.

BMC Res Notes. 2010 Jun 3;3(1):156. doi: 10.1186/1756-0500-3-156.

9.

Nociceptin/orphanin FQ suppresses adaptive immune responses in vivo and at picomolar levels in vitro.

Anton B, Leff P, Meissler JJ, Calva JC, Acevedo R, Salazar A, Matus M, Flores A, Martinez M, Adler MW, Gaughan JP, Eisenstein TK.

J Neuroimmune Pharmacol. 2010 Mar;5(1):143-54. doi: 10.1007/s11481-010-9190-2. Epub 2010 Feb 2.

10.

Vaccines against morphine/heroin and its use as effective medication for preventing relapse to opiate addictive behaviors.

Anton B, Salazar A, Flores A, Matus M, Marin R, Hernandez JA, Leff P.

Hum Vaccin. 2009 Apr;5(4):214-29. Epub 2009 Apr 8. Review.

PMID:
19242094
11.

Endomorphin 1 and endomorphin 2 suppress in vitro antibody formation at ultra-low concentrations: anti-peptide antibodies but not opioid antagonists block the activity.

Anton B, Leff P, Calva JC, Acevedo R, Salazar A, Matus M, Pavón L, Martinez M, Meissler JJ, Adler MW, Gaughan JP, Eisenstein TK.

Brain Behav Immun. 2008 Aug;22(6):824-32. doi: 10.1016/j.bbi.2008.02.004. Epub 2008 Apr 18.

12.

From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis.

Springthorpe B, Bailey A, Barton P, Birkinshaw TN, Bonnert RV, Brown RC, Chapman D, Dixon J, Guile SD, Humphries RG, Hunt SF, Ince F, Ingall AH, Kirk IP, Leeson PD, Leff P, Lewis RJ, Martin BP, McGinnity DF, Mortimore MP, Paine SW, Pairaudeau G, Patel A, Rigby AJ, Riley RJ, Teobald BJ, Tomlinson W, Webborn PJ, Willis PA.

Bioorg Med Chem Lett. 2007 Nov 1;17(21):6013-8. Epub 2007 Aug 19.

PMID:
17827008
13.

A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents.

Anton B, Leff P.

Vaccine. 2006 Apr 12;24(16):3232-40. Epub 2006 Feb 8.

PMID:
16494974
14.

Th2 cytokine response in Major Depressive Disorder patients before treatment.

Pavón L, Sandoval-López G, Eugenia Hernández M, Loría F, Estrada I, Pérez M, Moreno J, Avila U, Leff P, Antón B, Heinze G.

J Neuroimmunol. 2006 Mar;172(1-2):156-65. Epub 2006 Feb 2.

PMID:
16457895
15.

Orphanin-FQ/nociceptin inhibits kindling epileptogenesis and enhances hippocampal feed-forward inhibition.

Gutiérrez R, Leff P, Romo-Parra H, Acevedo R, Antón B.

Neuroscience. 2001;105(2):325-33.

PMID:
11672600
16.

Theoretical implications of receptor coupling to multiple G proteins based on analysis of a three-state model.

Scaramellini C, Leff P.

Methods Enzymol. 2002;343:17-29. No abstract available.

PMID:
11665565
17.

Adventures in the pharmacological analysis of P2 receptors.

Fagura MS, Jarvis GE, Dougall IG, Leff P.

J Auton Nerv Syst. 2000 Jul 3;81(1-3):178-86. Review.

PMID:
10869718
18.

ADP can induce aggregation of human platelets via both P2Y(1) and P(2T) receptors.

Jarvis GE, Humphries RG, Robertson MJ, Leff P.

Br J Pharmacol. 2000 Jan;129(2):275-82.

19.

A three-state receptor model: predictions of multiple agonist pharmacology for the same receptor type.

Scaramellini C, Leff P.

Ann N Y Acad Sci. 1998 Dec 15;861:97-103.

PMID:
9928245
20.

Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy.

Ingall AH, Dixon J, Bailey A, Coombs ME, Cox D, McInally JI, Hunt SF, Kindon ND, Teobald BJ, Willis PA, Humphries RG, Leff P, Clegg JA, Smith JA, Tomlinson W.

J Med Chem. 1999 Jan 28;42(2):213-20.

PMID:
9925726
21.

Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus.

Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, Clarke WP.

Mol Pharmacol. 1998 Jul;54(1):94-104.

PMID:
9658194
22.

P2Y1-receptors in human platelets which are pharmacologically distinct from P2Y(ADP)-receptors.

Fagura MS, Dainty IA, McKay GD, Kirk IP, Humphries RG, Robertson MJ, Dougall IG, Leff P.

Br J Pharmacol. 1998 May;124(1):157-64.

23.

Promiscuity, pre-coupling and instability.

Leff P, Scaramellini C.

Trends Pharmacol Sci. 1998 Jan;19(1):13. No abstract available.

PMID:
9509895
24.

A three-state receptor model of agonist action.

Leff P, Scaramellini C, Law C, McKechnie K.

Trends Pharmacol Sci. 1997 Oct;18(10):355-62. Review.

PMID:
9357320
25.

Analysis of agonist-agonist interactions: the crucial influence of curve shape.

Scaramellini C, Bennett G, Leff P.

J Pharmacol Toxicol Methods. 1997 Apr;37(3):167-78.

PMID:
9253753
26.

Interaction of BW A868C, a prostanoid DP-receptor antagonist, with two receptor subtypes in the rabbit isolated saphenous vein.

Lydford SJ, McKechnie KC, Leff P.

Prostaglandins. 1996 Aug;52(2):125-39. Erratum in: Prostaglandins 1997 Jan;53(1):59-62.

PMID:
8880898
27.

Partial agonist effects of BW A868C, a selective DP receptor antagonist, on Cl- secretion in dog tracheal epithelium.

Liu YJ, Jackson DM, Blackham A, Leff P.

Eur J Pharmacol. 1996 May 23;304(1-3):117-22.

PMID:
8813592
28.

The two-state model of agonist action: challenges to pharmacological receptor theory.

Leff P.

Proc West Pharmacol Soc. 1996;39:67-8. Review. No abstract available.

PMID:
8895972
29.

Synthesis of Hexahydrocyclopentimidazol-2-(1H)-one derivatives displaying selective DP-receptor agonist properties.

Barraclough P, Bolofo ML, Giles H, Gillam J, Harris CJ, Kelly MG, Leff P, McNeill A, Robertson AD, Stepney RJ, Whittle BJ.

Bioorg Med Chem. 1996 Jan;4(1):81-90.

PMID:
8689243
30.

Painful connection for ATP.

Kennedy C, Leff P.

Nature. 1995 Oct 5;377(6548):385-6. No abstract available.

PMID:
7566110
31.

Inverse agonism: theory and practice.

Leff P.

Trends Pharmacol Sci. 1995 Aug;16(8):256. No abstract available.

PMID:
7482981
32.

Pharmacological profile of the novel P2T-purinoceptor antagonist, FPL 67085 in vitro and in the anaesthetized rat in vivo.

Humphries RG, Tomlinson W, Clegg JA, Ingall AH, Kindon ND, Leff P.

Br J Pharmacol. 1995 Jul;115(6):1110-6.

33.

A novel series of P2T purinoceptor antagonists: definition of the role of ADP in arterial thrombosis.

Humphries RG, Robertson MJ, Leff P.

Trends Pharmacol Sci. 1995 Jun;16(6):179-81. Review. No abstract available.

PMID:
7652925
34.

International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. IX. Recommendations on terms and symbols in quantitative pharmacology.

Jenkinson DH, Barnard EA, Hoyer D, Humphrey PP, Leff P, Shankley NP.

Pharmacol Rev. 1995 Jun;47(2):255-66. Review. No abstract available.

PMID:
7568328
35.

How should P2X purinoceptors be classified pharmacologically?

Kennedy C, Leff P.

Trends Pharmacol Sci. 1995 May;16(5):168-74. Review.

PMID:
7624972
36.

Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the beta 2-adrenoceptor.

Bond RA, Leff P, Johnson TD, Milano CA, Rockman HA, McMinn TR, Apparsundaram S, Hyek MF, Kenakin TP, Allen LF, et al.

Nature. 1995 Mar 16;374(6519):272-6.

PMID:
7885448
37.

The two-state model of receptor activation.

Leff P.

Trends Pharmacol Sci. 1995 Mar;16(3):89-97.

PMID:
7540781
38.

Pharmacological and biochemical analysis of FPL 67156, a novel, selective inhibitor of ecto-ATPase.

Crack BE, Pollard CE, Beukers MW, Roberts SM, Hunt SF, Ingall AH, McKechnie KC, IJzerman AP, Leff P.

Br J Pharmacol. 1995 Jan;114(2):475-81.

39.
40.

FPL 66096: a novel, highly potent and selective antagonist at human platelet P2T-purinoceptors.

Humphries RG, Tomlinson W, Ingall AH, Cage PA, Leff P.

Br J Pharmacol. 1994 Nov;113(3):1057-63.

41.

Agonist-antagonist interactions at angiotensin receptors: application of a two-state receptor model.

Robertson MJ, Dougall IG, Harper D, McKechnie KC, Leff P.

Trends Pharmacol Sci. 1994 Oct;15(10):364-9. Review.

PMID:
7809951
42.

Theoretical treatment of one-agonist-two-receptor systems.

Leff P.

Trends Pharmacol Sci. 1994 Sep;15(9):320; author reply 321-2. No abstract available.

PMID:
7992383
43.

Nomenclature and classification of purinoceptors.

Fredholm BB, Abbracchio MP, Burnstock G, Daly JW, Harden TK, Jacobson KA, Leff P, Williams M.

Pharmacol Rev. 1994 Jun;46(2):143-56. Review. No abstract available.

44.
45.

Further concerns over Cheng-Prusoff analysis.

Leff P, Dougall IG.

Trends Pharmacol Sci. 1993 Apr;14(4):110-2.

PMID:
8516953
46.
47.

Adenosine 5'-(2-fluorodiphosphate) is not a selective P2Y purinoceptor agonist in the rabbit jugular vein.

Wood BE, O'Connor SE, Leff P.

J Pharmacol Exp Ther. 1992 Aug;262(2):566-9.

PMID:
1501113
49.

Self-understanding and reaching out to sick children and their families: an ongoing professional challenge.

Leff PT, Chan JM, Walizer EM.

Child Health Care. 1991 Fall;20(4):230-9.

PMID:
10115572
50.

Deviations from receptor theory?

Leff P, Dougall IG, Harper D.

Trends Pharmacol Sci. 1992 Feb;13(2):54-5. No abstract available.

PMID:
1561713

Supplemental Content

Support Center